Otsuka (OTCMKTS:OTSKY) Sees Large Volume Increase – Time to Buy?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares saw an uptick in trading volume on Monday . 26,906 shares were traded during mid-day trading, a decline of 31% from the previous session’s volume of 38,936 shares.The stock last traded at $34.10 and had previously closed at $32.97.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on OTSKY shares. Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Otsuka presently has an average rating of “Hold”.

Otsuka Stock Performance

The stock has a fifty day moving average of $34.45 and a 200-day moving average of $32.47. The firm has a market capitalization of $35.37 billion and a P/E ratio of 13.89. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05.

Otsuka (OTCMKTS:OTSKY) last released its earnings results on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The firm had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, research analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 EPS for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.